false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Autosom ...
ADPKD-Focused Drug Therapies
ADPKD-Focused Drug Therapies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
York Pei reviewed disease-modifying therapies for autosomal dominant polycystic kidney disease (ADPKD), focusing on PKD1 and PKD2. Their protein products, polycystin-1 and polycystin-2, work together in kidney cells. Disease severity varies by mutation type, and cysts often arise after a second, somatic mutation. Additional factors may help small cysts grow into clinically significant macrocysts, which enlarge total kidney volume and damage surrounding tissue.<br /><br />Tolvaptan, which blocks vasopressin signaling and lowers cyclic AMP, remains the established disease-modifying treatment. It can slow kidney growth and functional decline, but has important risks and tolerability limitations.<br /><br />Potential emerging therapies target the PAPP-A/IGF pathway, metabolic changes such as reduced AMPK activity, microRNA-17, and specific PKD1 mutations. Gene replacement—particularly PKD2—or correction of missense mutations is promising but remains technically challenging, especially because delivering therapies effectively to kidney tissue is difficult. Pei emphasized that clinical trials are essential: promising preclinical results do not always translate to people, and combination therapies require careful testing.<br /><br />In discussion, he encouraged eligible patients to consider trials and noted that treatment selection must be guided by clinical evidence. He also explained that somatic mutations occur naturally, while gene therapy is likely still many years from routine use.
Asset Caption
York Pei, MD, FASN
Meta Tag
Speaker
York Pei
Keywords
autosomal dominant polycystic kidney disease
ADPKD
PKD1
PKD2
tolvaptan
vasopressin signaling
microRNA-17
gene therapy
×
Please select your language
1
English